Respiratory Antiviral Treatment Market Size, Share, and Trends 2024 to 2033

Respiratory Antiviral Treatment Market (By Disease Type: Pneumonia, Influenza, Bronchiolitis, Upper Respiratory Tract Infection, Others; By Drug Class: Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : June 2024
  • Report Code : 4549
  • Category : Healthcare

Respiratory Antiviral Treatment Market Size, Growth

The global respiratory antiviral treatment market is surging, with an overall revenue growth expectation of hundreds of millions of dollars from 2023 to 2032. The rising prevalence of heart disease sector across the world is driving the growth of the respiratory antiviral treatment market.

Respiratory Antiviral Treatment Market Size 2024 to 2033

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Respiratory Antiviral Treatment Market Key Takeaways

  • By region, North America led the respiratory antiviral treatment market with the largest share in 2023.
  • By region, Asia Pacific is expected to estimate to be the fastest rate of growth during the forecast period.
  • By drug class, the neuraminidase inhibitors segment led the market in 2023.
  • By drug class, the nucleoside analogs segment is expected to be the fastest growing segment during the forecast period.
  • By disease type, the influenza segment dominated the market in 2023.
  • By distribution channel, the hospital pharmacy segment dominated the respiratory antiviral treatment market in 2023.
  • By distribution channel, the retail pharmacy segment is estimated to grow with the significant CAGR during the forecast period.

Market Overview

The respiratory antiviral treatment market is one of the most important industries in the healthcare sector. This industry mainly deals in discovering, developing and manufacturing of antiviral therapies for treating respiratory problems. There are several types of antiviral drugs that mainly includes nucleoside analogs, neuraminidase inhibitors, ion channel blockers, fusion protein inhibitors and some others. These drugs are mainly distributed by a well-organised distribution channel including hospital pharmacy, retail pharmacy, online pharmacy and some other channels.

The technological developments related to medical industries along with rising government investment for strengthening healthcare sectors is likely to augment the market growth positively. This industry is expected to grow exponentially with the growth in the healthcare industry.

  • In March 2022, AbbVie collaborated with Scripps Research. This collaboration is done to develop antiviral therapies for treatment of COVID-19.

Respiratory Antiviral Treatment Market Growth Factors

  • The technological advancement in the medical industry is expected to drive the growth of the respiratory antiviral treatment market.
  • The rising government initiatives to strengthen the healthcare sector has driven the market growth.
  • The growing developments in the public and private hospitals across the world fosters the market growth.
  • The rise in number of government hospitals across the world has boosted the respiratory antiviral treatment market growth.
  • The growing investments from public and private sector entities for developing the antiviral treatment industries also boosts the market growth.
  • The rising integration of modern technologies in drug manufacturing is likely to impact the market growth positively.
  • The increase in number of telemedicine platforms also propels the market growth.
  • The rising demand for health insurance schemes around the world is expected to boost the respiratory antiviral treatment market growth.

Respiratory Antiviral Treatment Market Scope

Report Coverage Details
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Disease Type, Drug Class, Distribution Channel, and Regions
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Respiratory Antiviral Treatment Market Dynamics

Driver

Rising prevalence of chronic obstructive pulmonary disease (COPD)

The respiratory diseases are considered as a leading of cause of death among the people of the world. Among respiratory diseases, the chronic obstructive pulmonary disease (COPD) has the highest prevalence across the world and caused maximum deaths worldwide. According to a data published in March 2023 by the WHO (World Health Organisation), the chronic obstructive pulmonary disease (COPD) was the 3rd leading cause of death around the world. This disease is generally caused by air pollution and tobacco smoking among others. Thus, the rising cases of COPD among patients increases the demand for antiviral drugs that are effective against COPD, thereby driving the growth of the respiratory antiviral treatment market. Also, several biopharma companies have started developing antiviral therapies for treating COPD, which is likely to boost the market growth.

  • In November, 2023, Lupin launched Vilfuro-G. Vilfuro-G is a triple combination drug (FDC) that can be used in treatment of chronic obstructive pulmonary disease (COPD).

Restraint

High cost and side effects

The respiratory antiviral treatment industry has gained traction in recent times with the advances in drug development. Although, this industry is growing at a rapid pace but it faces several problems that impacts the market growth negatively. The cost of raw materials and wages of skilled workers in this industry is very high. Thus, in order to derive maximum profits, the manufacturers tend to increase the price of the finished product that restrains the market growth. Also, there are several side effects associated with respiratory antiviral treatments that mainly includes nausea, bronchospasm, diarrhoea, vomiting and some others, which in turn restrains the growth of the respiratory antiviral treatment market.

Opportunity

Integration of generative AI in antiviral drug delivery

The development in AI is an integral part for the development of antiviral therapeutics industry. The rising integration of generative AI in respiratory antiviral treatment has gained popularity in present times. With the use of generative AI, biopharma companies can develop superior quality antiviral therapeutics for treating several respiratory issues. Thus, rising integration of generative AI in antiviral drug manufacturing is expected to create ample growth opportunities for the market players in the future.

Drug Class Insights

The neuraminidase inhibitors segment held the largest respiratory antiviral treatment market share in 2023. The growth of this segment is generally driven by the rise in advancement in medical sciences. Also, rising development in the biopharma sectors along with the increasing investments for research and development activities of antiviral drugs is expected to drive the market growth.

The growing prevalence of influenza among the people across the world has increased the demand for neuraminidase inhibitors as neuraminidase inhibitors are effective for treating influenza disease. Thereby, driving the market growth. The main types of neuraminidase inhibitors in the market includes zanamivir, oseltamivir and some others. Moreover, several biotechnology companies are developing antiviral therapeutics and constantly engaged in conducting clinical trials of these medicines for treating respiratory diseases, that in turn drives the growth of the respiratory antiviral treatment market.

  • In April 2024, TaiGen announced that it had completed phase III trial of an antiviral medicine. This antiviral medicine is named as ‘TG-1000’ and it is found effective for treatment of influenza disease.

The nucleoside analogs segment is expected to be the fastest growing segment during the forecast period. The growth of this segment is generally driven by the growing cases of COVID-19 in some parts of the world. Also, growing initiatives of private sector entities for developing high-quality antiviral drugs for treatment of respiratory disorders boosts the growth of the respiratory antiviral treatment market.

The rise in number of research and innovation centres for developing antiviral drugs along with growing applications of pyrimidine inhibitors for treating SARS-CoV-2 infection drives the market growth. The most widely used nucleoside analogs includes acyclovir, ribavirin and some others, Moreover, nucleoside analogs are found effective against arthropod-borne flaviviruses that in turn is expected to boost the market growth.

Disease Type Insights

The influenza segment dominated the market in 2023. The growth of this segment is generally driven by the rising prevalence of H1N1 flu among the people across the world. Also, the growing demand for oseltamivir phosphate to treat acute influenza among infants is likely to boost the market growth. The rising cases of flu across the world increases the demand for antiviral therapeutics that boosts the growth of the respiratory antiviral treatment market during the forecast period. According to CDC (Centers for Disease Control and Prevention), around 27 to 54 million flu cases along with 19,000 - 58,000 deaths in the U.S during 2022 and 2023. Moreover, the biopharma companies are constantly engaged in developing high-grade antiviral medicines for treating influenza virus that is likely to drive the market growth.

  • In April 2024, Shionogi announced the launch of XOFLUZA in Taiwan. XOFLUZA is an effective antiviral drug for the treatment of influenza virus infection for pediatrics aged between 5 to 12 years.

The pneumonia segment is expected to grow at a notable rate during the forecast period. The growth of this segment is driven by the rising prevalence of pneumonia among the across the world. Also, rising demand for acyclovir for treating pneumonia patients is also expected to drive the market growth. Moreover, the rise in number of public hospitals with pneumonia treatment specialities is likely to propel the growth of the respiratory treatment market during the forecast period.

Distribution Channel Insights

The hospital pharmacy segment held the largest market share in the respiratory antiviral treatment market. The growth of this segment is generally driven by the rising developments in hospital infrastructure. Also, the rise in the government investments for developing modern hospitals with integrated pharmacies drives the market growth. Moreover, the availability of antiviral drugs for treatment of several respiratory diseases such as flu, influenza, COPD and some others in hospital pharmacies is likely to boost the growth of the respiratory antiviral treatment market.

The retail pharmacy segment is expected to be the significnatly growing segment during the forecast period. The growth of this segment is generally driven by the rise in number of retail pharmacies in different parts of the world. Also, the growing number of retail pharmacy chains across the world boosts the market growth. Moreover, rising development in the supply chain of pharmaceutical products along with increase in government initiatives for strengthening the retail pharmacy sector is expected to drive the growth of the respiratory antiviral treatment market.

Regional Insights

North America held the largest respiratory antiviral treatment market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of this region is mainly driven by the rising government initiatives in countries such as the U.S., Canada, Mexico and some others for strengthening the healthcare sector. The growing developments in the healthcare industry along with the presence of well-established biotechnology sector drives the market growth. Also, the rising advancements in science and technology along with the establishment of several drug research institutions and innovation centres is likely to drive the market growth.

Moreover, presence of several market players such as Johnson & Johnson Private Limited, Abbvie, Gilead Sciences, Inc., Pfizer, Merck & Co., Inc. and some others are constantly engaged in developing high-quality respiratory antiviral medicines and adopting several strategies such as launches, collaborations and acquisitions, which in turn drives the growth of the respiratory antiviral treatment market in this region.

  • For instance, in August 2022, the U.S. Department of Health and Human Services (HHS) announced an investment of 60 million USD to develop healthcare facilities in rural areas of U.S.A.
  • In June 2022, Pfizer Inc acquired ReViral. This acquisition will help Pfizer to use ReViral’s resources for developing, discovering, and commercialization of novel antiviral therapeutics that can be effective against respiratory syncytial virus (RSV).

Asia Pacific is expected to be the fastest growing region during the forecast period. The growth is mainly driven by the rising prevalence of pneumonia among the children in this region. According to the UNICEF (United Nations International Children's Emergency Fund) data, around 2500 children in per 100 children suffers from pneumonia in South Asia. Also, rising investments by public and private sector entities for developing the antiviral drugs sector is boosting the market growth. The growing incidences of influenza diseases in this region increases the demand for antiviral drugs for getting cured. Additionally, the rise in number of government hospitals with high quality doctors along with adequate pharmacy facilities has driven the market growth in this region.

Moreover, rise in government initiatives for strengthening the medical sector along with presence of several biopharma companies such as Teva Pharmaceuticals, Zydus Cadila, Dr. Reddy's Laboratories Ltd and some others are constantly engaged in developing respiratory antiviral medicines and adopting several strategies such as launches, partnerships and expansions, which is likely to drive the growth of the higher education market in this region.

  • In the 2023-2024 budget, the Ministry of Health and Family Welfare received a hefty amount Rs 89,155 crore from Indian government for matters related to health research and health & family welfare.
  • In March 2024, Shionogi & Co., Ltd made an announcement stating that the Ministry of Health, Labour and Welfare (MHLW) of Japan had approved Xocova. Xocova is an antiviral medication for treating COVID-19 patients.

Respiratory Antiviral Treatment Companies

Respiratory Antiviral Treatment Market Companies

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Cadila
  • Johnson & Johnson Private Limited
  • Amneal Pharmaceuticals LLC
  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Lupin
  • Gilead Sciences, Inc.
  • Cipla Inc.
  • Bausch Health Companies Inc.
  • Aurobindo Pharma
  • Hetero
  • Teva Pharmaceutical Industries Ltd.

Recent Developments

  • In June 2024, GSK plc announced that the US Food and Drug Administration (FDA) had approved Arexvy vaccine. Arexvy vaccine is used for the prevention of RSV lower respiratory tract disease (LRTD) in adults aged between 50-59 years of age.
  • In May 2024, Sanofi announced that the US Food and Drug Administration approved the extension of Dupixent (dupilumab) for three months as an add-on maintenance treatment for several adult patients suffering from uncontrolled chronic obstructive pulmonary disease (COPD).
  • In February 2024, Bioxytran launched ProLectin-M. ProLectin-M is an oral antiviral treatment for treatment of COVID-19.
  • In February 2024, Takeda announced that the FDA had approved EOHILIA. EOHILIA is an oral antiviral therapy for treating patients of age 11 years and above suffering from eosinophilic esophagitis (EoE).
  • In May 2022, the Centre for Drug Design and Discovery (CD3) and KU Leuven’s Rega Institute for Medical Research collaborated with Gilead Sciences, Inc. This collaboration is done to develop new antiviral medications for treating patients suffering from respiratory syncytial virus (RSV) infection.

Segments Covered in the Report

By Disease Type

  • Pneumonia
  • Influenza
  • Bronchiolitis
  • Upper Respiratory Tract Infection
  • Others

By Drug Class

  • Nucleoside Analogs
  • Neuraminidase Inhibitors
  • Ion Channel Blockers
  • Fusion Protein Inhibitors

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The major players operating in the respiratory antiviral treatment market are F. Hoffmann-La Roche Ltd., Mylan N.V., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, Johnson & Johnson Private Limited, Amneal Pharmaceuticals LLC, AbbVie Inc., Alembic Pharmaceuticals Limited, Lupin, Gilead Sciences, Inc., Cipla Inc., Bausch Health Companies Inc., Aurobindo Pharma, Hetero, Teva Pharmaceutical Industries Ltd., and Others.

The driving factors of the respiratory antiviral treatment market are an increase in number of telemedicine platforms and rising demand for health insurance schemes.

North America region will lead the global respiratory antiviral treatment market during the forecast period 2024 to 2033.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client